China: Patent Law Amendment brings sea change to pharmaceutical patent regime

Published date05 November 2020
Subject MatterPatents,Life Sciences,China,Biotechnology,Prescription Drugs,Regulatory Agenda,Generic Drugs,Patent Applications,Pharmaceutical Patents,Intellectual Property Protection,Pharmaceutical Industry,Linkage Litigation Schemes,CNIPA
AuthorVictor Ho
Law FirmAllen & Overy LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT